Showing 38,381 - 38,400 results of 103,067 for search '(( 2 step decrease ) OR ( 5 ((nn decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.60s Refine Results
  1. 38381
  2. 38382
  3. 38383
  4. 38384
  5. 38385

    CPA treatment lowered activated caspase 3 and GFAP levels while DPCPX increased activated Caspase 3 and GFAP levels. by Manuel Soliño (5410001)

    Published 2018
    “…F) Quantification of C3a by WB. DPCPX produced a highly significant rise in C3a relative density compared to CTL (1.85±0.5 vs 1.01±0.07; unpaired Student´s t-test; p<0.01; n = 4), **p<0.01.…”
  6. 38386

    Data_Sheet_1_Gut microbiota of preterm infants in the neonatal intensive care unit: a study from a tertiary care center in northern India.docx by Prabavathi Devarajalu (17929847)

    Published 2024
    “…DNA was extracted using a DNeasy Powersoil DNA isolation kit. 16S rRNA gene sequencing targeting the V3–V4 region was performed using the MiSeq platform. …”
  7. 38387

    A comprehensive study of glucose and oxygen gradients in a scaled-down model of recombinant HuGM-CSF production in thermoinduced <i>Escherichia coli</i> fed-batch cultures by Greta I. Reynoso-Cereceda (18501789)

    Published 2024
    “…</p> <p></p><p>Thermoinduced recombinant <i>E. coli</i> grew less in a two-compartment scale-down model.</p><p>Heat-inducible <i>E. coli</i> cultures at a large scale significantly decrease recombinant protein production.…”
  8. 38388
  9. 38389

    Image_1_Modification of Intestinal Microbiota Dysbiosis by Low-Dose Interleukin-2 in Dermatomyositis: A Post Hoc Analysis From a Clinical Trial Study.jpeg by Yunzhi Zhufeng (10961908)

    Published 2022
    “…Low-dose IL-2 treatment emerges as a new option for active IIMs. This study aims to explore the role of low-dose IL-2 in regulating intestinal dysbiosis involved in the IIMs. …”
  10. 38390

    Image_3_Modification of Intestinal Microbiota Dysbiosis by Low-Dose Interleukin-2 in Dermatomyositis: A Post Hoc Analysis From a Clinical Trial Study.jpeg by Yunzhi Zhufeng (10961908)

    Published 2022
    “…Low-dose IL-2 treatment emerges as a new option for active IIMs. This study aims to explore the role of low-dose IL-2 in regulating intestinal dysbiosis involved in the IIMs. …”
  11. 38391

    Table_1_Modification of Intestinal Microbiota Dysbiosis by Low-Dose Interleukin-2 in Dermatomyositis: A Post Hoc Analysis From a Clinical Trial Study.docx by Yunzhi Zhufeng (10961908)

    Published 2022
    “…Low-dose IL-2 treatment emerges as a new option for active IIMs. This study aims to explore the role of low-dose IL-2 in regulating intestinal dysbiosis involved in the IIMs. …”
  12. 38392

    Table_1_Modification of Intestinal Microbiota Dysbiosis by Low-Dose Interleukin-2 in Dermatomyositis: A Post Hoc Analysis From a Clinical Trial Study.docx by Yunzhi Zhufeng (10961908)

    Published 2022
    “…Low-dose IL-2 treatment emerges as a new option for active IIMs. This study aims to explore the role of low-dose IL-2 in regulating intestinal dysbiosis involved in the IIMs. …”
  13. 38393

    Image_1_Modification of Intestinal Microbiota Dysbiosis by Low-Dose Interleukin-2 in Dermatomyositis: A Post Hoc Analysis From a Clinical Trial Study.jpeg by Yunzhi Zhufeng (10961908)

    Published 2022
    “…Low-dose IL-2 treatment emerges as a new option for active IIMs. This study aims to explore the role of low-dose IL-2 in regulating intestinal dysbiosis involved in the IIMs. …”
  14. 38394

    Image_2_Modification of Intestinal Microbiota Dysbiosis by Low-Dose Interleukin-2 in Dermatomyositis: A Post Hoc Analysis From a Clinical Trial Study.jpeg by Yunzhi Zhufeng (10961908)

    Published 2022
    “…Low-dose IL-2 treatment emerges as a new option for active IIMs. This study aims to explore the role of low-dose IL-2 in regulating intestinal dysbiosis involved in the IIMs. …”
  15. 38395

    Image_3_Modification of Intestinal Microbiota Dysbiosis by Low-Dose Interleukin-2 in Dermatomyositis: A Post Hoc Analysis From a Clinical Trial Study.jpeg by Yunzhi Zhufeng (10961908)

    Published 2022
    “…Low-dose IL-2 treatment emerges as a new option for active IIMs. This study aims to explore the role of low-dose IL-2 in regulating intestinal dysbiosis involved in the IIMs. …”
  16. 38396

    Image_2_Modification of Intestinal Microbiota Dysbiosis by Low-Dose Interleukin-2 in Dermatomyositis: A Post Hoc Analysis From a Clinical Trial Study.jpeg by Yunzhi Zhufeng (10961908)

    Published 2022
    “…Low-dose IL-2 treatment emerges as a new option for active IIMs. This study aims to explore the role of low-dose IL-2 in regulating intestinal dysbiosis involved in the IIMs. …”
  17. 38397

    Regulation by a shared sRNA synchronizes the temporal induction of mRNA expression. by Jörn Matthias Schmiedel (141779)

    Published 2012
    “…The heatmaps show simulation results for a regulatory scenario where a coordinate, step-like increase (C) or decrease (panel D) in both mRNA synthesis rates is accompanied by a step-like change in the sRNA synthesis rate in the opposite direction; this counter-regulation assumption was necessary to eliminate delay phases, and to obtain the same steady states in sRNA and sRNA-less systems. …”
  18. 38398

    DataSheet_1_Identification and experimental validation of cuproptosis regulatory program in a sepsis immune microenvironment through a combination of single-cell and bulk RNA seque... by Tingru Zhao (17368789)

    Published 2024
    “…Patients with higher CuAS exhibited prominent strength and numbers of cell–cell interactions. A total of five CRGs were identified based on the LASSO and Cox regression analyses, and a CRG-based risk model was established. …”
  19. 38399

    Analysis of glycine and proliferation <i>in vitro</i> as a function of SHMT2 and sodium benzoate. by Jiefei Tong (426705)

    Published 2020
    “…Intracellular metabolites were extracted and analyzed by selected reaction monitoring mass spectrometry, SRM, n = 5 to 8 biological replicates. (A) In HeLa-Ss cells relative levels of intracellular glycine levels were measured as a function of endogenous SHMT2 expression (control; C) or elevated (+) or decreased (–) expression of SHTM2 (described above), and without (–) or with (+) glycine supplementation in growth medium. …”
  20. 38400